CardioGenics Holdings Inc. is a Canada-based development-stage company. The Company develops technology and products targeting the immunoassay segment of the in vitro diagnostic (IVD) testing market. The Company’s products include: QL Care Analyzer (QLCA), Cardiovascular Tests and Paramagnetic Beads. The QLCA represents a shift in the design of point-of-care (POC) analyzers. To support the use of the QLCA, the Company has developed four immunoassay tests designed to identify cardiac markers in the blood at the time of a heart attack. These tests include Troponin I (TnI), Plasminogen Activator Inhibitor Type-1 (PAI-1), Heart Failure Risk Stratification (HFRS) and Heart Failure Genomics Risk (HFGR). Pramagnetic (magnetic) beads are the common solid phase employed during immunoassays tests in these laboratories. The Company has developed a process that coats the beads with a layer of silver, making them white and more sensitive to light.
|Headquarters||6865 SW 18th St Ste B13|
BOCA RATON, FL, United States 33433-7057
|Acting Independent Chairman of the Board||J.Neil Tabatznik|
|Chief Executive Officer, Director||Yahia Gawad|
|Chief Financial Officer||James Essex|
|Corporate Secretary, Director||Linda Sterling|
|Independent Director||Karim Murabet|
|Shares Out.||58.5M||Book Value||$-0.02|
|CardioGenics Holdings Inc does not pay a dividend.||P/E||--|
|P/Cash Flow (TTM)||--|
*GAAP = prior to non-GAAP analyst adjusted earnings.